Event Type
Disclosure
Mandatory
Variant
8-K
. Entry Into a Material Definitive Agreement On December 18, 2025, Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), entered into a Se
of this Form 8-K have the respective meanings ascribed thereto by the Share Exchange Agreement and the Royalty Agreement, as applicable. Item 8.01. Other Events
Financial Statements and Exhibits (d) Exhibits. The following exhibits are filed herewith. Exhibit Number Description 4.1 Form of Pre-Funded Warrant 4.2 Form of